Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04189588 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
A Phase 2 study, sponsored by TerSera Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT04189588 is a Phase 2 study that has completed, run by TerSera Therapeutics. The registered enrollment target is 34 participants.
The verdict
NCT04189588, a Phase 2 study, has completed, sponsored by TerSera Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study is designed to compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions while on maintenance or retreatment.
Interventions
- DRUG Cetirizine HCl 10 mg/mL
- DRUG Diphenhydramine 50 mg/mL
- DRUG anti-CD20 such as Rituximab or Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-03-25 |
| Est. Completion | 2020-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04189588
The ClinicalTrials.gov registry entry for NCT04189588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TerSera Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetirizine HCl 10 mg/mL is the first listed.
NCT04189588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04189588 about?
NCT04189588 is a clinical study titled "Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine". This study is designed to compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment w...
What is the current status of trial NCT04189588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2020-03-25. Estimated completion is 2020-12-23.
What interventions are being tested in trial NCT04189588?
The interventions under investigation include: Cetirizine HCl 10 mg/mL (DRUG), Diphenhydramine 50 mg/mL (DRUG), anti-CD20 such as Rituximab or Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT04189588?
This trial is sponsored by TerSera Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.